General Information
Version
1.0
Revision date
2019-10-29
Product name
Viramune tablets (finished product)
Product Synonyms
Viramune® 50mg tablets, Viramune® 200mg tablets, Vira- mune® 400mg tablets, Viramune® XR 50 mg tablets, Vira- mune® XR 100 mg tablets, Viramune® XR 400 mg tablets. Active ingredient: Nevirapine
1.2.1 Relevant identified uses
Pharmaceutical
1.2.2. Uses advised against
Safety Data Sheet only for the professional user on use
Icons in SDS
Company Information
company name
Boehringer Ingelheim Vetmedica
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H302, H412
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Classification
Signal word
Warning
Hazard statements
H302 Harmful if swallowed. H412 Harmful to aquatic life with long lasting effects.
Prevention
P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P273 Avoid release to the environment.
Response
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.
Disposal
P501 Dispose of contents/ container to an approved waste disposal plant.
Hazardous Ingredients
Nevirapine
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher. The pharmacological effect of the medicament has to be considered (see package leaflet). This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS)
